Cigna prior authorization for M0235: Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of COVID-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose
Code
M0235
Description
Intravenous infusion, monoclonal antibody products with an indication
for post-exposure prophylaxis or treatment of COVID-19, for
hospitalized adults and/or pediatric patients who are receiving systemic
corticosteroids and require supplemental oxygen, non-invasive or
invasive mechanical ventilation, or extracorporeal membrane
oxygenation (ecmo) only, includes infusion and post administration
monitoring, not otherwise classified, first dose
Source
Master Precertification List
For Health Care Providers, Pg 92 Original policy
The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.
Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.
Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.
This website uses cookies to ensure you get the best experience on our website. Learn more
